Get in touch
555-555-5555
mymail@mailservice.com
TolerogenixX
Founding year:
Management:
Head office:
Industry:
Investment phase:
2015
Anita Schmitt,
Dr. Matthias Schaier
Prof. Dr. Christian Morath
Heidelberg
Medicine / pharma
Start-up phase
TolerogenixX, a spin-off from the University of Heidelberg, offers a new approach to immunosuppression involving MIC cell therapy.
This is a curative ATMP approach to treatment that promotes sustainable regulation of the immune system in people who have received transplants or patients with autoimmune diseases.